UBS and Citi Go Bullish on Gilead Sciences (GILD)

Gilead Sciences, Inc. (NASDAQ:GILD) is one of the most undervalued blue chip stocks to buy now.

UBS and Citi Go Bullish on Gilead Sciences (GILD)

On January 7, 2026, reports highlighted that analysts are increasingly confident in Gilead Sciences, Inc. (NASDAQ:GILD)’s short- and medium-term outlook, driven by optimism around the company’s HIV franchise. On that day, UBS analyst Michael Yee upgraded the stock from ‘Neutral’ to ‘Buy’ and raised the firm’s price target from $112 to $145, according to The Fly. The analyst expects strong HIV pre-exposure prophylaxis sales from Yeztugo, which could potentially boost both revenue and earnings. At the same time, the analyst expects visibility into the company’s outer-year growth trajectory to improve. Furthermore, Yee highlighted the company’s focus on prevention-based HIV therapies, which reflects a strategic evolution of the company’s core antiviral business toward more durable, growth-oriented demand drivers.

This positive update was accompanied by another on the same day, with Citi’s analyst Geoff Meacham raising the firm’s target from $135 to $140 and maintaining a ‘Buy’ rating.

The bullish analyst sentiment was reinforced earlier, on December 22, 2025, when Gilead Sciences, Inc. (NASDAQ:GILD) exercised its option to exclusively license Assembly Biosciences’ long-acting HSV helicase-primase inhibitor programs, ABI-1179 and ABI-5366. The deal, supported by positive Phase 1b data and once-weekly oral dosing potential, extends the company’s goal of expanding its antiviral pipeline into areas with significant unmet need and limited competition. This move supports the company’s long-term growth optionality beyond HIV.

Gilead Sciences, Inc. (NASDAQ:GILD), a biopharmaceutical company, focuses on the development and commercialization of innovative medicines across HIV, liver disease, oncology, hematology, and inflammatory conditions.

While we acknowledge the potential of GILD to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than GILD and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 7 Best Rising Tech Stocks to Buy Now and 12 Best Multibagger Stocks to Buy Heading into 2026.

Disclosure: None.